|
InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies.
Publication: Blood Weekly Publication Date: 02-OCT-08 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2008 NewsRX
InNexus Biotechnology Inc. (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF; http://www.ixsbio.com/), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced the results of an extensive mouse tumor study demonstrating superiority of InNexus' DXL625 (CD20) versus Rituxan(R) in the...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Blood Weekly |
Limiting resident surgeon's work hours associated with fewer complicat...
October 02, 2008
|
Study points to 1 cause of higher rates of transplanted kidney rejecti...
October 02, 2008
|
Motorcyclists 'Cruisin' Through Oakland County for Children's Leukemia...
October 02, 2008
|
LifeModeler, Inc. Provides $400,000 Grant to InMotion Musculoskeletal ...
October 02, 2008
|
Lung Cancer in Non-Smokers Is Sixth Biggest Cancer Killer.
October 02, 2008
|
|
| Find companies classified under Biological products exc diagnostic |
| Find companies classified under Commercial physical research |
| Find companies classified under Pharmaceutical preparations |
| Find companies classified under Drugs proprietaries and sundries |
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
